Noticias y Actividades de Sorrento Therapeutics

Sorrento Therapeutics es una empresa que cotiza bajo el símbolo de cotización SRNE (US).

Ver el organigrama con sus 28 ejecutivos principales

Biografías más buscadas en Sorrento Therapeutics

• Henry Ji, Chairman, President and Chief Executive Officer
• Dave Lemus, Director
• Yue Wu, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Sorrento Therapeutics.

Sorrento Therapeutics tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado el 12 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Paul Meister - Chairman of the Board en Amneal Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Sorrento Therapeutics

• Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster | Sorrento Therapeutics
• Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc. | Sorrento Therapeutics
• News Releases | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors | Sorrento Therapeutics
• Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. | So
• Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes | Sorrento Therapeutics
• Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans | Sorrento Therapeutics
• View more press releases Close

Redes sociales sobre Sorrento Therapeutics

• Sorrento Therapeutics en Wikipedia, Google News y Yahoo Finance
• Sorrento Therapeutics en LinkedIn, Twitter y YouTube